{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:06:16Z","timestamp":1779807976532,"version":"3.53.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"University of Cape Town"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40261-026-01538-y","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:13:26Z","timestamp":1773386006000},"page":"595-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost Effectiveness of First-Line Therapies for Treatment-Na\u00efve Chronic Lymphocytic Leukaemia in South Africa"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1840-1176","authenticated-orcid":false,"given":"Rochelle","family":"Woudberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edina","family":"Sinanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"2","key":"1538_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/17474086.2020.1697225","volume":"13","author":"R Moia","year":"2020","unstructured":"Moia R, Patriarca A, Deambrogi C, et al. An update on: molecular genetics of high-risk chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13(2):109\u201316. https:\/\/doi.org\/10.1080\/17474086.2020.1697225.","journal-title":"Expert Rev Hematol"},{"key":"1538_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102818","volume":"97","author":"R Woudberg","year":"2025","unstructured":"Woudberg R, Meiring SM, Sinanovic E. Leukemia epidemiology and burden of disease in South Africa: 2015\u20132019. Cancer Epidemiol. 2025;97:102818. https:\/\/doi.org\/10.1016\/j.canep.2025.102818.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"1538_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12938-021-00973-6","volume":"21","author":"Y Yao","year":"2022","unstructured":"Yao Y, Lin X, Li F, et al. The global burden and attributable risk factors of chronic lymphocytic leukaemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022;21(1):4. https:\/\/doi.org\/10.1186\/s12938-021-00973-6.","journal-title":"Biomed Eng Online"},{"key":"1538_CR4","unstructured":"Explorer S. Surveillance Epidemiology and End Results (SEER) Program, Cancer Stat Facts: Leukaemia\u2014Chronic Lymphocytic Leukaemia (CLL). 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html#:~:text=at%20a%20Glance-,At%20a%20Glance,89.3%25%202015%E2%80%932021."},{"issue":"11","key":"1538_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review. JAMA. 2023;329(11):918\u201332. https:\/\/doi.org\/10.1001\/jama.2023.1946.","journal-title":"JAMA"},{"issue":"1","key":"1538_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019.","journal-title":"Ann Oncol"},{"key":"1538_CR7","doi-asserted-by":"publisher","first-page":"17008","DOI":"10.1038\/nrdp.2017.8","volume":"3","author":"TJ Kipps","year":"2017","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:17008. https:\/\/doi.org\/10.1038\/nrdp.2017.8.","journal-title":"Nat Rev Dis Primers"},{"key":"1538_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26683","author":"JA Woyach","year":"2022","unstructured":"Woyach JA. Management of relapsed\/refractory chronic lymphocytic leukaemia. Am J Hematol. 2022. https:\/\/doi.org\/10.1002\/ajh.26683.","journal-title":"Am J Hematol"},{"key":"1538_CR9","unstructured":"Abbvie. IMBRUVICA\u00ae (ibrutinib) approved by U.S. FDA for the first-line treatment of chronic lymphocytic leukaemia. 2016. https:\/\/news.abbvie.com\/2016-03-04-IMBRUVICA-ibrutinib-Approved-by-U-S-FDA-for-the-First-line-Treatment-of-Chronic-Lymphocytic-Leukaemia. Accessed 02 Oct 2024."},{"key":"1538_CR10","unstructured":"FDA. FDA approves venetoclax for CLL and SLL. 2019. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll. Accessed 02 Oct 2024."},{"issue":"6","key":"1538_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","volume":"20","author":"WG Wierda","year":"2022","unstructured":"Wierda WG, Brown J, Abramson JS, et al. NCCN Guidelines\u00ae insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 3.2022: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2022;20(6):622\u201334. https:\/\/doi.org\/10.6004\/jnccn.2022.0031.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"1538_CR12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40273-021-01010-z","volume":"39","author":"H Vellekoop","year":"2021","unstructured":"Vellekoop H, Huygens S, Versteegh M, et al. Guidance for the harmonisation and improvement of economic evaluations of personalised medicine. Pharmacoeconomics. 2021;39(7):771\u201388. https:\/\/doi.org\/10.1007\/s40273-021-01010-z.","journal-title":"Pharmacoeconomics"},{"key":"1538_CR13","doi-asserted-by":"publisher","DOI":"10.7196\/sajph.2024.v7i2.1875","author":"D Mueller","year":"2024","unstructured":"Mueller D, Poluta M, Brand M, et al. Professionalising health technology assessment in South Africa. Southern Afr J Public Health. 2024. https:\/\/doi.org\/10.7196\/sajph.2024.v7i2.1875.","journal-title":"Southern Afr J Public Health."},{"issue":"4","key":"1538_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A Briggs","year":"1998","unstructured":"Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397\u2013409. https:\/\/doi.org\/10.2165\/00019053-199813040-00003.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1538_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/s0266462322000265","volume":"38","author":"M Wilkinson","year":"2022","unstructured":"Wilkinson M, Gray AL, Wiseman R, et al. Health Technology Assessment in Support of National Health Insurance in South Africa. Int J Technol Assess Health Care. 2022;38(1):1\u201332. https:\/\/doi.org\/10.1017\/s0266462322000265.","journal-title":"Int J Technol Assess Health Care"},{"key":"1538_CR16","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s79258","author":"O Mandrik","year":"2015","unstructured":"Mandrik O, Corro Ramos I, Knies S, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukaemia in Ukraine. Cancer Manag Res. 2015. https:\/\/doi.org\/10.2147\/cmar.s79258.","journal-title":"Cancer Manag Res."},{"issue":"4","key":"1538_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1177\/0272989x16670617","volume":"37","author":"C Williams","year":"2017","unstructured":"Williams C, Lewsey JD, Mackay DF, et al. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling. Med Decis Making. 2017;37(4):427\u201339. https:\/\/doi.org\/10.1177\/0272989x16670617.","journal-title":"Med Decis Making"},{"issue":"2","key":"1538_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40273-013-0125-7","volume":"32","author":"M Adena","year":"2014","unstructured":"Adena M, Houltram J, Mulligan SP, et al. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse. Pharmacoeconomics. 2014;32(2):193\u2013207. https:\/\/doi.org\/10.1007\/s40273-013-0125-7.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1538_CR19","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3109\/10428194.2011.605918","volume":"53","author":"J Hornberger","year":"2012","unstructured":"Hornberger J, Reyes C, Shewade A, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(2):225\u201334. https:\/\/doi.org\/10.3109\/10428194.2011.605918.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1538_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40273-023-01346-8","volume":"42","author":"DW Kang","year":"2024","unstructured":"Kang DW, Wang L, Short NJ, et al. Cost effectiveness of Zanubrutinib versus Ibrutinib in relapsed or refractory chronic lymphocytic leukaemia. Pharmacoeconomics. 2024;42(4):409\u201318. https:\/\/doi.org\/10.1007\/s40273-023-01346-8.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1538_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40259-023-00583-9","volume":"37","author":"L Lorenzovici","year":"2023","unstructured":"Lorenzovici L, Szilberhorn L, Farkas-Raduly S, et al. Systematic literature review of economic evaluations of treatment alternatives in chronic lymphocytic leukaemia. BioDrugs. 2023;37(2):219\u201333. https:\/\/doi.org\/10.1007\/s40259-023-00583-9.","journal-title":"BioDrugs"},{"issue":"9747","key":"1538_CR22","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(10)61381-5.","journal-title":"Lancet"},{"issue":"26","key":"1538_CR23","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/nejmoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517\u201328. https:\/\/doi.org\/10.1056\/nejmoa1812836.","journal-title":"N Engl J Med"},{"issue":"1","key":"1538_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s1470-2045(18)30788-5","volume":"20","author":"C Moreno","year":"2019","unstructured":"Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43\u201356. https:\/\/doi.org\/10.1016\/s1470-2045(18)30788-5.","journal-title":"Lancet Oncol"},{"issue":"23","key":"1538_CR25","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/nejmoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225\u201336. https:\/\/doi.org\/10.1056\/nejmoa1815281.","journal-title":"N Engl J Med"},{"issue":"11","key":"1538_CR26","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2021006434.","journal-title":"Blood Adv"},{"issue":"11","key":"1538_CR27","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1182\/bloodadvances.2023012142","volume":"8","author":"AS Kittai","year":"2024","unstructured":"Kittai AS, Allan JN, James D, et al. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024;8(11):2861\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023012142.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"1538_CR28","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1182\/blood-2022-156948","volume":"140","author":"N Alrawashdh","year":"2022","unstructured":"Alrawashdh N, McBride A, Abraham I. Cost-effectiveness analyses of first line ibrutinib versus acalabrutinib versus zanubrutinib followed by second line venetoclax plus rituximab in previously untreated chronic lymphocytic leukaemia (CLL) patients. Blood. 2022;140(Supplement 1):2155\u20136. https:\/\/doi.org\/10.1182\/blood-2022-156948.","journal-title":"Blood"},{"key":"1538_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251340554","volume":"17","author":"M Shadman","year":"2025","unstructured":"Shadman M, Brown JR, Williams R, et al. Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukaemia (R\/R CLL): a matching-adjusted indirect comparison (MAIC). Ther Adv Med Oncol. 2025;17:17588359251340554. https:\/\/doi.org\/10.1177\/17588359251340554.","journal-title":"Ther Adv Med Oncol"},{"key":"1538_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades A, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:1\u201313. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1538_CR31","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","volume":"17","author":"Y Wei","year":"2017","unstructured":"Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan\u2013Meier curves. Stata J Promot Commun Stat Stata. 2017;17(4):786\u2013802. https:\/\/doi.org\/10.1177\/1536867X1801700402.","journal-title":"Stata J Promot Commun Stat Stata"},{"issue":"8","key":"1538_CR32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1177\/0272989X16656165","volume":"36","author":"J Chhatwal","year":"2016","unstructured":"Chhatwal J, Jayasuriya S, Elbasha EH. Changing cycle lengths in state-transition models: challenges and solutions. Med Decis Making. 2016;36(8):952\u201364. https:\/\/doi.org\/10.1177\/0272989X16656165.","journal-title":"Med Decis Making"},{"issue":"12","key":"1538_CR33","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/nejmoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax\u2013Rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107\u201320. https:\/\/doi.org\/10.1056\/nejmoa1713976.","journal-title":"N Engl J Med"},{"key":"1538_CR34","unstructured":"Health SANDo. Database of medicine prices 30 August 2024. 2024. https:\/\/www.health.gov.za\/nhi-pee\/. Accessed 22 Sept 2024."},{"issue":"5","key":"1538_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16050980","volume":"16","author":"MA Anderson","year":"2024","unstructured":"Anderson MA, Walewska R, Hackett F, et al. Venetoclax initiation in chronic lymphocytic leukaemia: international insights and innovative approaches for optimal patient care. Cancers (Basel). 2024;16(5):980. https:\/\/doi.org\/10.3390\/cancers16050980.","journal-title":"Cancers (Basel)"},{"key":"1538_CR36","unstructured":"Africa NS. National Department of Health South Africa. Uniform Patient Fee Schedule Tarriffs Tshwane; 2024. https:\/\/www.health.gov.za\/uniform-patient-fee-schedule\/. Accessed 17 Dec 2024."},{"key":"1538_CR37","unstructured":"NHLS. NHLS State Price List 2018. 2018. https:\/\/www.nhls.ac.za\/. Accessed 22 Sept 2024."},{"issue":"5","key":"1538_CR38","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","volume":"56","author":"CE Kosmas","year":"2015","unstructured":"Kosmas CE, Shingler SL, Samanta K, et al. Health state utilities for chronic lymphocytic leukaemia: importance of prolonging progression-free survival. Leuk Lymphoma. 2015;56(5):1320\u20136. https:\/\/doi.org\/10.3109\/10428194.2014.961012.","journal-title":"Leuk Lymphoma"},{"key":"1538_CR39","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"issue":"5","key":"1538_CR40","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/heapol\/czz152","volume":"35","author":"IP Edoka","year":"2020","unstructured":"Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan. 2020;35(5):546\u201355. https:\/\/doi.org\/10.1093\/heapol\/czz152.","journal-title":"Health Policy Plan"},{"issue":"8","key":"1538_CR41","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929\u201335. https:\/\/doi.org\/10.1016\/j.jval.2016.02.017.","journal-title":"Value Health"},{"issue":"9","key":"1538_CR42","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"S Sharma","year":"2019","unstructured":"Sharma S, Rai KR. Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options. Cancer. 2019;125(9):1432\u201340. https:\/\/doi.org\/10.1002\/cncr.31931.","journal-title":"Cancer"},{"issue":"5","key":"1538_CR43","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3109\/10428194.2015.1070151","volume":"57","author":"D Muller","year":"2016","unstructured":"Muller D, Fischer K, Kaiser P, et al. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukaemia. Leuk Lymphoma. 2016;57(5):1130\u20139. https:\/\/doi.org\/10.3109\/10428194.2015.1070151.","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"1538_CR44","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood.2020004922","volume":"136","author":"KK Patel","year":"2020","unstructured":"Patel KK, Isufi I, Kothari S, et al. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukaemia. Blood. 2020;136(17):1946\u201355. https:\/\/doi.org\/10.1182\/blood.2020004922.","journal-title":"Blood"},{"issue":"15","key":"1538_CR45","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/bloodadvances.2017015461","volume":"2","author":"JI Barnes","year":"2018","unstructured":"Barnes JI, Divi V, Begaye A, et al. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukaemia in older adults without deletion 17p. Blood Adv. 2018;2(15):1946\u201356. https:\/\/doi.org\/10.1182\/bloodadvances.2017015461.","journal-title":"Blood Adv"},{"issue":"11","key":"1538_CR46","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.18553\/jmcp.2021.27.11.1532","volume":"27","author":"A Chatterjee","year":"2021","unstructured":"Chatterjee A, Shapouri S, Manzoor BS, et al. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukaemia in the United States. J Manag Care Spec Pharm. 2021;27(11):1532\u201344. https:\/\/doi.org\/10.18553\/jmcp.2021.27.11.1532.","journal-title":"J Manag Care Spec Pharm"},{"issue":"15","key":"1538_CR47","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1182\/bloodadvances.2023010108","volume":"7","author":"M Slot","year":"2023","unstructured":"Slot M, Niemann CU, Ehlers LH, et al. Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations. Blood Adv. 2023;7(15):4186\u201396. https:\/\/doi.org\/10.1182\/bloodadvances.2023010108.","journal-title":"Blood Adv"},{"issue":"11","key":"1538_CR48","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00277-023-05342-y","volume":"102","author":"NC Hegde","year":"2023","unstructured":"Hegde NC, Kumar A, Kaundal S, et al. Generic ibrutinib a potential cost-effective strategy for the first-line treatment of chronic lymphocytic leukaemia. Ann Hematol. 2023;102(11):3125\u201332. https:\/\/doi.org\/10.1007\/s00277-023-05342-y.","journal-title":"Ann Hematol"},{"issue":"4","key":"1538_CR49","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jval.2021.10.004","volume":"25","author":"L Everest","year":"2022","unstructured":"Everest L, Blommaert S, Chu RW, et al. Parametric survival extrapolation of early survival data in economic analyses: a comparison of projected versus observed updated survival. Value Health. 2022;25(4):622\u20139. https:\/\/doi.org\/10.1016\/j.jval.2021.10.004.","journal-title":"Value Health"},{"key":"1538_CR50","unstructured":"State Patient Price List 2023\u20132024. 2024. https:\/\/www.sanbs.org.za\/product-price-list\/. Accessed 22 Sept 2024."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01538-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01538-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01538-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:48:34Z","timestamp":1779806914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01538-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1538"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01538-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval was granted by the University of Cape Town Human Research Ethics Committee (HREC; ref. 923\/2023). All methods were conducted in accordance with institutional guidelines and relevant national regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The study was a retrospective data review with no enrolment of human subjects, therefore no informed consent was necessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The Microsoft Excel-based Markov model and associated calculation code used in this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All data generated or analysed during this study are included in this article. The clinical and survival data used to derive model inputs were sourced from published clinical trials cited in the References section. Reconstructed survival datasets and model parameter inputs are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"All authors contributed to the study conception. RW was responsible for the study design, development of the economic model, data analysis and interpretation, and drafting of this article. ES contributed to the drafting\/revision of the manuscript and data interpretation. All authors read and approved the final manuscript version and agree to be accountable for this work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}